ACBP: Scientists Identify Key Protein Driving Bone Metastasis, Pointing to New Therapeutic Strategies
/in CRISPR, Preclinical Research/by MaxPT-112: FDA Clears Phase 3 Trial of Novel Therapy for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 3/by MaxPembrolizumab Plus Enzalutamide Therapy Shows No Benefit in Metastatic Castration-Resistant Prostate Cancer Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxNewsletter 20/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! New week of news. This time we also have some very positive updates about the CRISPR gene editing method. Although it doesn’t directly relate to prostate cancer, it’s something very important. Stay strong and fight on! As usual, we […]
Real-World Prostate Cancer Treatments Are Better Than Clinical Trial Results, Study Finds
/in Retrospective studies/by MaxInnovations in Prostate Cancer Treatment: Antibody-Based Radioligand Therapy and Combinations Show Promise
/in Review/by MaxCRISPR is Here to Stay: Gene Therapy Succesfully Used On An Infant With Incurable Disease
/in Not PCa related/by MaxTargeting the Undruggable: SCORT–Cas13d Nanotherapy Against Metastatic Prostate Cancer
/in CRISPR, Preclinical Research/by MaxNewsletter 19/2025
/in Newsletter/by MaxLAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! After two weeks of indigestion from new clinical trials and preclinical studies due to the international conferences AACR 2025 and AUA 2025, we’re back to a more modest amount of information—but no less interesting because of it! Stay strong […]
Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 21/2026 May 24, 2026
- A-DREAM Trial Suggests Some Men with Metastatic Prostate Cancer May Stop Therapy Safely for a Time May 22, 2026
- Phase 2 TALENT Trial: Talazoparib as Monotherapy or With Enzalutamide in HRR-deficient mCRPC May 22, 2026
- ABBV-969 in mCRPC: Dual‑Targeting ADC Shows Robust PSA and Objective Responses in Heavily Pretreated Patients May 22, 2026